Your browser doesn't support JavaScript. Please upgrade to a modern browser or enable JavaScript in your existing browser.
Skip Navigation U.S. Department of Health and Human Services www.hhs.gov
Agency for Healthcare Research Quality www.ahrq.gov
Archive print banner

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to www.ahrq.gov for current information.

Table 3. Primary Prevention Trials of Drug Therapy: Results*

Study details LRC (34) Helsinki (35) WOSCOPS (36) AFCAPS(37)
Year 1984 1987 1995 1998
Main outcome Nonfatal MI, CHD death Nonfatal MI, CHD death Nonfatal MI, CHD death Nonfatal MI, CHD death, unstable angina
Cumulative event ratea 8.1/9.8 2.73/4.14 5.5/7.9 3.4/5.45
I/C (5.5/6.6)b     1.65/2.9c
ARR 1.7 (1.1)b 1.41 2.4 2.05 (1.25)c
NNT for 5 yearse (91)b 71 42 49 (80)c
RRR (%) 19 34 31 37
(95% CI) (3-32)d (8-53) (17-43) (21-50)

[a] Event rates are cumulative incidence in percentages for the event over the study; I, intervention, C, control.
[b] Adjusted 5-year outcomes for LRC.
[c] Unstable angina excluded in results.
[d] CI for LRC was 90%.
[e] NNT for 5 years to prevent 1 CHD event.

*LRC, Lipids Research Council; HHS, Helsinki Heart Study; WOSCOPS, West of Scotland Coronary Prevention Study; AFCAPS, Air Force/Texas Coronary Atherosclerosis Prevention; MI, myocardial infarction; CHD, coronary heart disease; ARR, absolute risk reduction; NNT, numbers needed to treat; RRR, relative risk reduction; CI, confidence interval.

Return to Document

 

The information on this page is archived and provided for reference purposes only.

 

AHRQ Advancing Excellence in Health Care